<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04676139</url>
  </required_header>
  <id_info>
    <org_study_id>SSRI &amp; Nocturnal enuresis</org_study_id>
    <nct_id>NCT04676139</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy of Fluoxetine for Refractory Primary Mono-symptomatic Nocturnal Enuresis in Children</brief_title>
  <official_title>The Safety and Efficacy of Selective Serotonin Reuptake Inhibitors, Fluoxetine, for Refractory Primary Mono-symptomatic Nocturnal Enuresis in Children: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether there is a role for the selective serotonin reuptake inhibitors,&#xD;
      fluoxetine, as therapy in the treatment of refractory primary monosymptomatic nocturnal&#xD;
      enuresis in children , and whether there are side effects involved.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A randomized controlled clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>assess efficacy Selective Serotonin Reuptake Inhibitors, Fluoxetine, for refractory Primary Mono-symptomatic Nocturnal Enuresis in children.</measure>
    <time_frame>6 months</time_frame>
    <description>counting the wet nights numbers between baseline and after 2 weeks of each treatment period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>assess the safety of Selective Serotonin Reuptake Inhibitors, Fluoxetine, for refractory Primary Mono-symptomatic Nocturnal Enuresis in children.</measure>
    <time_frame>6 months</time_frame>
    <description>by counting the numbers of complication of each drugs</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Nocturnal Enuresis</condition>
  <arm_group>
    <arm_group_label>Fluoxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will undergo maintenance therapy selective serotonin reuptake inhibitors, fluoxetine, 10 mg capsules once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients will undergo maintenance therapy Placebo for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoxetine</intervention_name>
    <description>Fluoxetine 10 mg capsules once daily for 12 months</description>
    <arm_group_label>Fluoxetine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo for 12 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary Monosymptomatic nocturnal enuresis&#xD;
&#xD;
          -  Failed treatment with desmopressin.&#xD;
&#xD;
          -  The enuresis alarm had either been tried without effect, or deemed unfeasible because&#xD;
             of the family situation.&#xD;
&#xD;
          -  All patients had either tried and failed combination therapy with anticholinergics or,&#xD;
             because of contraindications, been unable to receive such therapy.&#xD;
&#xD;
          -  Severe enuresis with at least seven wet nights out of 14&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Underlying renal, urologic, neurologic, endocrinologic, or cardiac conditions&#xD;
&#xD;
          -  Depression&#xD;
&#xD;
          -  Severe psychiatric diseases&#xD;
&#xD;
          -  Untreated constipation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahmoud Elkenawy</last_name>
    <role>Study Chair</role>
    <affiliation>Professor of urology Urology and Nephrology center Faculty of medicine Mansoura university</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tamer El-sayed Helmy</last_name>
    <role>Study Director</role>
    <affiliation>Associate Professor of urology Urology and Nephrology center Faculty of medicine Mansoura university</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmed Abdelhalem</last_name>
    <role>Study Director</role>
    <affiliation>Lecturer of urology Urology and Nephrology center Faculty of medicine Mansoura university</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed Hussiny abdelazim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Resident in Urology Urology and Nephrology canter Mansoura University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamed Hussiny abdelazim</last_name>
    <phone>01064156383</phone>
    <phone_ext>+2</phone_ext>
    <email>mohamedhussiny1@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mansoura urology and nephrology center</name>
      <address>
        <city>Mansoura</city>
        <state>Dakahlia</state>
        <zip>0502263717</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Hussiny abdelazim</last_name>
      <phone>01064156383</phone>
      <phone_ext>+2</phone_ext>
      <email>mohamedhussiny1@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <results_reference>
    <citation>Nevéus T. Pathogenesis of enuresis: Towards a new understanding. Int J Urol. 2017 Mar;24(3):174-182. doi: 10.1111/iju.13310. Epub 2017 Feb 16. Review.</citation>
    <PMID>28208214</PMID>
  </results_reference>
  <results_reference>
    <citation>Neveus T, Eggert P, Evans J, Macedo A, Rittig S, Tekgül S, Vande Walle J, Yeung CK, Robson L; International Children's Continence Society. Evaluation of and treatment for monosymptomatic enuresis: a standardization document from the International Children's Continence Society. J Urol. 2010 Feb;183(2):441-7. doi: 10.1016/j.juro.2009.10.043. Epub 2009 Dec 14.</citation>
    <PMID>20006865</PMID>
  </results_reference>
  <results_reference>
    <citation>Song P, Huang C, Wang Y, Wang Q, Zhu W, Yue Y, Wang W, Feng J, He X, Cui L, Wan T, Wen J. Comparison of desmopressin, alarm, desmopressin plus alarm, and desmopressin plus anticholinergic agents in the management of paediatric monosymptomatic nocturnal enuresis: a network meta-analysis. BJU Int. 2019 Mar;123(3):388-400. doi: 10.1111/bju.14539. Epub 2018 Oct 31. Review.</citation>
    <PMID>30216627</PMID>
  </results_reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 5, 2020</study_first_submitted>
  <study_first_submitted_qc>December 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2020</study_first_posted>
  <last_update_submitted>December 15, 2020</last_update_submitted>
  <last_update_submitted_qc>December 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Nocturnal Enuresis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluoxetine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

